Literature DB >> 33741915

Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment.

Min Zhang1, Jin-Li Luo2, Qianqian Sun1, James Harber3, Alan G Dawson3,4, Apostolos Nakas4, Sara Busacca3, Annabel J Sharkey5, David Waller6, Michael T Sheaff6, Cathy Richards7, Peter Wells-Jordan7, Aarti Gaba3, Charlotte Poile3, Essa Y Baitei3,8, Aleksandra Bzura3, Joanna Dzialo3, Maymun Jama3, John Le Quesne9, Amrita Bajaj10, Luke Martinson3, Jacqui A Shaw3, Catrin Pritchard3, Tamihiro Kamata3, Nathaniel Kuse3, Lee Brannan11, Pan De Philip Zhang12, Hongji Yang12, Gareth Griffiths13, Gareth Wilson14, Charles Swanton14, Frank Dudbridge11, Edward J Hollox3, Dean A Fennell15.   

Abstract

Malignant Pleural Mesothelioma (MPM) is typically diagnosed 20-50 years after exposure to asbestos and evolves along an unknown evolutionary trajectory. To elucidate this path, we conducted multi-regional exome sequencing of 90 tumour samples from 22 MPMs acquired at surgery. Here we show that exomic intratumour heterogeneity varies widely across the cohort. Phylogenetic tree topology ranges from linear to highly branched, reflecting a steep gradient of genomic instability. Using transfer learning, we detect repeated evolution, resolving 5 clusters that are prognostic, with temporally ordered clonal drivers. BAP1/-3p21 and FBXW7/-chr4 events are always early clonal. In contrast, NF2/-22q events, leading to Hippo pathway inactivation are predominantly late clonal, positively selected, and when subclonal, exhibit parallel evolution indicating an evolutionary constraint. Very late somatic alteration of NF2/22q occurred in one patient 12 years after surgery. Clonal architecture and evolutionary clusters dictate MPM inflammation and immune evasion. These results reveal potentially drugable evolutionary bottlenecking in MPM, and an impact of clonal architecture on shaping the immune landscape, with potential to dictate the clinical response to immune checkpoint inhibition.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33741915      PMCID: PMC7979861          DOI: 10.1038/s41467-021-21798-w

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  49 in total

1.  Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR.

Authors:  Hui Yang; Kai Wang
Journal:  Nat Protoc       Date:  2015-09-17       Impact factor: 13.491

2.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.

Authors:  Raphael Bueno; Eric W Stawiski; Leonard D Goldstein; Steffen Durinck; Assunta De Rienzo; Zora Modrusan; Florian Gnad; Thong T Nguyen; Bijay S Jaiswal; Lucian R Chirieac; Daniele Sciaranghella; Nhien Dao; Corinne E Gustafson; Kiara J Munir; Jason A Hackney; Amitabha Chaudhuri; Ravi Gupta; Joseph Guillory; Karen Toy; Connie Ha; Ying-Jiun Chen; Jeremy Stinson; Subhra Chaudhuri; Na Zhang; Thomas D Wu; David J Sugarbaker; Frederic J de Sauvage; William G Richards; Somasekar Seshagiri
Journal:  Nat Genet       Date:  2016-02-29       Impact factor: 38.330

3.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Authors:  Matthew Bott; Marie Brevet; Barry S Taylor; Shigeki Shimizu; Tatsuo Ito; Lu Wang; Jenette Creaney; Richard A Lake; Maureen F Zakowski; Boris Reva; Chris Sander; Robert Delsite; Simon Powell; Qin Zhou; Ronglai Shen; Adam Olshen; Valerie Rusch; Marc Ladanyi
Journal:  Nat Genet       Date:  2011-06-05       Impact factor: 38.330

Review 4.  Novel insights into mesothelioma biology and implications for therapy.

Authors:  Timothy A Yap; Joachim G Aerts; Sanjay Popat; Dean A Fennell
Journal:  Nat Rev Cancer       Date:  2017-07-25       Impact factor: 60.716

5.  Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

Authors:  Dean A Fennell; Paul Baas; Paul Taylor; Anna K Nowak; David Gilligan; Takashi Nakano; Jonathan A Pachter; David T Weaver; Arnaud Scherpereel; Nick Pavlakis; Jan P van Meerbeeck; Susana Cedrés; Luke Nolan; Hedy Kindler; Joachim G J V Aerts
Journal:  J Clin Oncol       Date:  2019-02-20       Impact factor: 44.544

6.  Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney Cancer.

Authors:  Zhong-Qiang Guo; Tong Zheng; Baoen Chen; Cheng Luo; Sisheng Ouyang; Shouzhe Gong; Jiafei Li; Liu-Liang Mao; Fulin Lian; Yong Yang; Yue Huang; Li Li; Jing Lu; Bidong Zhang; Luming Zhou; Hong Ding; Zhiwei Gao; Liqun Zhou; Guoqiang Li; Ran Zhou; Ke Chen; Jingqiu Liu; Yi Wen; Likun Gong; Yuwen Ke; Shang-Dong Yang; Xiao-Bo Qiu; Naixia Zhang; Jin Ren; Dafang Zhong; Cai-Guang Yang; Jiang Liu; Hualiang Jiang
Journal:  Cancer Cell       Date:  2016-09-12       Impact factor: 31.743

7.  MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.

Authors:  Katya Marjon; Michael J Cameron; Phong Quang; Michelle F Clasquin; Everton Mandley; Kaiko Kunii; Michael McVay; Sung Choe; Andrew Kernytsky; Stefan Gross; Zenon Konteatis; Joshua Murtie; Michelle L Blake; Jeremy Travins; Marion Dorsch; Scott A Biller; Kevin M Marks
Journal:  Cell Rep       Date:  2016-04-07       Impact factor: 9.423

8.  Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.

Authors:  Maria J Disselhorst; Josine Quispel-Janssen; Ferry Lalezari; Kim Monkhorst; Jeltje F de Vries; Vincent van der Noort; Emmy Harms; Sjaak Burgers; Paul Baas
Journal:  Lancet Respir Med       Date:  2019-01-16       Impact factor: 30.700

9.  Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Authors:  Julija Hmeljak; Francisco Sanchez-Vega; Katherine A Hoadley; Juliann Shih; Chip Stewart; David Heiman; Patrick Tarpey; Ludmila Danilova; Esther Drill; Ewan A Gibb; Reanne Bowlby; Rupa Kanchi; Hatice U Osmanbeyoglu; Yoshitaka Sekido; Jumpei Takeshita; Yulia Newton; Kiley Graim; Manaswi Gupta; Carl M Gay; Lixia Diao; David L Gibbs; Vesteinn Thorsson; Lisa Iype; Havish Kantheti; David T Severson; Gloria Ravegnini; Patrice Desmeules; Achim A Jungbluth; William D Travis; Sanja Dacic; Lucian R Chirieac; Françoise Galateau-Sallé; Junya Fujimoto; Aliya N Husain; Henrique C Silveira; Valerie W Rusch; Robert C Rintoul; Harvey Pass; Hedy Kindler; Marjorie G Zauderer; David J Kwiatkowski; Raphael Bueno; Anne S Tsao; Jenette Creaney; Tara Lichtenberg; Kristen Leraas; Jay Bowen; Ina Felau; Jean Claude Zenklusen; Rehan Akbani; Andrew D Cherniack; Lauren A Byers; Michael S Noble; Jonathan A Fletcher; A Gordon Robertson; Ronglai Shen; Hiroyuki Aburatani; Bruce W Robinson; Peter Campbell; Marc Ladanyi
Journal:  Cancer Discov       Date:  2018-10-15       Impact factor: 39.397

10.  Loss of BAP1 function leads to EZH2-dependent transformation.

Authors:  Lindsay M LaFave; Wendy Béguelin; Richard Koche; Matt Teater; Barbara Spitzer; Alan Chramiec; Efthymia Papalexi; Matthew D Keller; Todd Hricik; Katerina Konstantinoff; Jean-Baptiste Micol; Benjamin Durham; Sarah K Knutson; John E Campbell; Gil Blum; Xinxu Shi; Emma H Doud; Andrei V Krivtsov; Young Rock Chung; Inna Khodos; Elisa de Stanchina; Ouathek Ouerfelli; Prasad S Adusumilli; Paul M Thomas; Neil L Kelleher; Minkui Luo; Heike Keilhack; Omar Abdel-Wahab; Ari Melnick; Scott A Armstrong; Ross L Levine
Journal:  Nat Med       Date:  2015-10-05       Impact factor: 53.440

View more
  21 in total

Review 1.  Immunotherapy approaches for malignant pleural mesothelioma.

Authors:  Dean A Fennell; Sean Dulloo; James Harber
Journal:  Nat Rev Clin Oncol       Date:  2022-07-01       Impact factor: 65.011

2.  Cannabidiol promotes apoptosis of osteosarcoma cells in vitro and in vivo by activating the SP1-CBX2 axis.

Authors:  Fangxing Xu; Guiyuan Sun; Zhibin Peng; Jingsong Liu; Zecheng Li; Jinglong Yan
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

3.  Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.

Authors:  Patrick M Forde; Valsamo Anagnostou; Zhuoxin Sun; Suzanne E Dahlberg; Hedy L Kindler; Noushin Niknafs; Thomas Purcell; Rafael Santana-Davila; Arkadiusz Z Dudek; Hossein Borghaei; Mara Lanis; Zineb Belcaid; Kellie N Smith; Archana Balan; James R White; Christopher Cherry; I K Ashok Sivakumar; Xiaoshan M Shao; Hok Yee Chan; Dipika Singh; Sampriti Thapa; Peter B Illei; Drew M Pardoll; Rachel Karchin; Victor E Velculescu; Julie R Brahmer; Suresh S Ramalingam
Journal:  Nat Med       Date:  2021-11-08       Impact factor: 53.440

4.  Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia.

Authors:  Brooks A Benard; Logan B Leak; Armon Azizi; Daniel Thomas; Andrew J Gentles; Ravindra Majeti
Journal:  Nat Commun       Date:  2021-12-13       Impact factor: 14.919

5.  Surgical Diagnosis of Malignant Pleural Mesothelioma: 20 Years' Experience at a High-Volume Referral Center.

Authors:  Amedeo Iaffaldano; Thomas Charrier; Filippo Lococo; Diane Damotte; Antonio Bobbio; Marco Alifano; Ludovic Fournel
Journal:  J Clin Med       Date:  2021-05-04       Impact factor: 4.241

6.  Precision Therapy for Mesothelioma: Feasibility and New Opportunities.

Authors:  Sean Dulloo; Aleksandra Bzura; Dean Anthony Fennell
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

Review 7.  Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma.

Authors:  Benjamin Wadowski; Raphael Bueno; Assunta De Rienzo
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

8.  Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma.

Authors:  Hélène Brossel; Alexis Fontaine; Clotilde Hoyos; Majeed Jamakhani; Mégane Willems; Malik Hamaidia; Luc Willems
Journal:  Cancers (Basel)       Date:  2021-06-27       Impact factor: 6.639

Review 9.  Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma.

Authors:  Stefanie Hiltbrunner; Laura Mannarino; Michaela B Kirschner; Isabelle Opitz; Angelica Rigutto; Alexander Laure; Michela Lia; Paolo Nozza; Antonio Maconi; Sergio Marchini; Maurizio D'Incalci; Alessandra Curioni-Fontecedro; Federica Grosso
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

Review 10.  Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma.

Authors:  Moshe Lapidot; Srinivas Vinod Saladi; Ravi Salgia; Martin Sattler
Journal:  Front Pharmacol       Date:  2022-01-07       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.